[On Demand]
ID4Pharma (or ID4) is a University-Pittsburgh technology-based startup and is a leading innovator for anti-Multiple Myeloma (MM) new drug discovery. ID4 has developed a global patent technology of a first-in-class SQSTM1 target-specific anti-MM new drug: Sequesta®. ID4 was a winner of SBIR ‘Fast Track’ grant award for FDA IND-enabling studies.
Sequesta® has its competitive advantages in treatment of MM disease relapse, particularly for MM patients who develop drug resistance. Another its uniqueness is its dual therapeutics of high in vivo efficacy of inhibiting MM tumor growth and also improving the tumor-bearing bone density without drug resistance observed. ID4 has completed the FDA IND-enabling studies, showing high efficacy and low GLP-toxicity in rat and monkey. ID4 is ready to move the new drug to human phase IB/IIA clinical trials with a full speed fast-track commercialization toward the MM drug market. We seek strategic partners and VCs for Phase IB/IIA clinical trials.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
First in class target-specific anti multiple Myeloma drug
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Founder/CSO & Chairman of the Board